Colorectal Cancer

A comprehensive review of outcome data from the SUNLIGHT clinical trial in patients with refractory metastatic colorectal cancer.

Marwan G. Fakih, MD, reviews the study design for the SUNLIGHT clinical trial investigating trifluridine-tipiracil plus bevacizumab in patients with refractory metastatic CRC.

A brief overview of treatment options available for patients with colorectal cancer prior to the SUNLIGHT study.

Comprehensive insights on the stratification, diagnosis, and treatment of patients with metastatic colorectal cancer.

Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, introduce themselves and give an overview of metastatic colorectal cancer (mCRC).

A study conducted by the American Cancer Society found patients who were Black received worse care for colorectal cancer treatment, with health insurance is the leading cause of racial disparities.

Drs Cohen, Wu, and Ahn discuss HER2 in colorectal cancer, explaining that increased expression indicates possible benefit from HER2 inhibitors; Ahn summarized studies showing modest activity of dual HER2 inhibition compared to single agent trastuzumab.

Drs Wu, Ciombor, and Cohen discussed upfront molecular testing in patients with colorectal cancer to guide treatment, with Dr Ciombor reviewing HER2 testing methods and Dr Cohen noting liquid biopsy limitations.

Arvind N. Dasari, MD, lead investigator of the FRESCO-2 trial, spoke about the recent approval of fruquintinib for patients with previously treated metastatic colorectal cancer.

Results from the phase 3 FRESCO-2 trial support the approval of fruquintinib for patients with previously treated metastatic colorectal cancer.

CHM 2101 will be assessed as part of a phase 1A/B clinical study in a population of patients diagnosed with advanced colorectal cancer, gastric cancer, and neuroendocrine cancer.

Drs Ahn and Cohen discuss the treatment of colorectal cancer, reviewing the available options and describing factors influencing treatment choice and use of maintenance therapy after initial response.

Stacy A. Cohen, MD, provides an overview of colorectal cancer, noting increasing incidence in younger patients; Christina S. Wu, MB, BCh, MD, discussed possible reasons for more colorectal cancer in younger people, including genetic predisposition and exposures, though the causes remain unclear.

Survival following relapse appears to be shorter in patients with stage III colon cancer harboring KRAS exon 2 and BRAF V600E mutations regardless of microsatellite stability status.

Sotorasib plus panitumumab demonstrate consistent efficacy across key patient subgroups with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations in the phase 3 CodeBreaK 300 trial.

Approval of the CRCdx RAS Mutation Detection Kit may improve access to panitumumab for the treatment of patients with colorectal cancer.

Tanios S. Bekaii-Saab, MD, gave an overview of colorectal cancer along with current standard of care, and potential treatment options.

Data from the phase 2 SAMCO-PRODIGE 54 trial may support the use of immune checkpoint inhibitors over standard second-line therapy in mismatch repair–deficient and/or microsatellite instability–high metastatic colorectal cancer.

Christina Wu, MB, BCh, MD, closes the program by expressing the necessity of enrolling patients with BRAF-mutant metastatic colorectal cancer in clinical trials, highlighting a second-line study led by the Southwest Oncology Group, new BRAF inhibitors, early phase studies at the Mayo Clinic, and an exciting study in the adjuvant setting.

Christina Wu, MB, BCh, MD, shares data from the phase 3 BREAKWATER trial, which assesses first-line targeted treatment strategies for patients with BRAF V600E-mutant metastatic colorectal cancer.

Investigators report that MRI by itself seems to be an inadequate tool for determining pathologic complete response in rectal adenocarcinoma during total neoadjuvant therapy.

Daniel Ahn, DO, describes the BEACON study, a randomized phase 3 trial in metastatic colorectal cancer that led to the FDA approval of a doublet regimen.

Christina Wu, MB, BCh, MD, discusses BRAF V600E mutations in metastatic colorectal cancer, including the various detection methods, the different classes of BRAF mutations, and the evolution of targeting treatments.

Daniel Walden, MD, presents the scenario of a 66-year-old man diagnosed with BRAF V600E-mutant metastatic colorectal cancer to the expert panel for discussion.

In a detailed conversation, Tanios Bekaii-Saab, MD, Daniel Ahn, DO, and Christina Wu, MB, BCh, MD, discuss various scenarios for treating HER2+ metastatic colorectal cancer, focusing on patient profiling, testing methods, and different sequencing strategies including the use of trastuzumab.

Daniel Ahn, DO, and Tanios Bekaii-Saab, MD, detail the findings of the DESTINY-CRC02 trial, which examined the efficacy of trastuzumab deruxtecan at different dosing levels in breast cancer and gastric cancer patients.

Christina Wu, MB, BCh, MD, shares the study design and efficacy data of the MOUNTAINEER-01 study, which explored combination tucatinib plus trastuzumab for the treatment of patients with HER2+ metastatic colorectal cancer.

Arvind N. Dasari, MD, and Cathy Eng, MD, gave an overview on the use of fruquintinib in colorectal cancer.

Daniel Walden, MD, presents the scenario of a 65-year-old man diagnosed with HER2+ metastatic colorectal cancer to the expert panel for discussion.

Experts emphasize the importance of acquiring both tissue and circulating tumor DNA (ctDNA) for molecular testing in patients with metastatic colorectal cancer, address challenges such as lack of tissue and costs, and highlight the role of HER2 as a biomarker.